Question 1

What is Insmed's EV/EBITDA ratio?

Accepted Answer

Insmed (INSM) EV/EBITDA ratio is currently not available. When EBITDA is negative, EV/EBITDA is reported as N/A. EV/Sales is the standard substitute for early-stage or temporarily loss-making companies.

Question 2

How is the EV/EBITDA ratio calculated?

Accepted Answer

EV/EBITDA = Enterprise Value ÷ Trailing Twelve-Month (TTM) EBITDA, where Enterprise Value = Market Capitalisation + Total Debt − Cash & Short-Term Investments. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the EV/EBITDA ratio?

Accepted Answer

The EV/EBITDA ratio (the enterprise multiple) compares enterprise value (EV) to trailing twelve-month (TTM) EBITDA. EV is calculated as market capitalisation + total debt − cash & short-term investments. Because EV/EBITDA is capital-structure-neutral and ignores non-cash depreciation and amortisation, it is the standard multiple used in M&A and for cross-company or cross-border comparisons. Note: this calculation uses a simplified EV (minority interest and preferred equity excluded due to data availability), consistent with most public financial-data providers.

Question 4

What is a good EV/EBITDA ratio for Insmed?

Accepted Answer

Mature, cash-generative businesses commonly trade in the 8–12× EV/EBITDA range; higher-growth, asset-light companies often trade at 15–25×+. EV/EBITDA is most useful for comparing companies with different capital structures (debt levels) or tax regimes. For Insmed specifically, the relevant sector benchmark is the current sector median of 15.0×.

Question 5

What is Insmed's historical EV/EBITDA ratio range?

Accepted Answer

In the available daily series, Insmed (INSM) EV/EBITDA ratio has ranged from a low of -0.2× in 2009 to a high of 0.8× in 2009.

Question 6

What was Insmed's EV/EBITDA ratio in 2009?

Accepted Answer

Insmed (INSM) EV/EBITDA ratio at the end of 2009 was -0.2×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month EBITDA figure available at that date.

Question 7

Why does Insmed's EV/EBITDA ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (enterprise value, which tracks share price plus net debt) and the denominator (EBITDA). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.

Question 8

Why is Insmed's EV/EBITDA ratio not available?

Accepted Answer

When EBITDA is negative, EV/EBITDA is reported as N/A. EV/Sales is the standard substitute for early-stage or temporarily loss-making companies.


2025	$37.18B	−$1.18B	—	—	Dec 31, 2025
2024	$12.36B	−$818.79M	—	—	Dec 31, 2024
2023	$4.49B	−$660.18M	—	—	Dec 31, 2023
2022	$2.65B	−$449.83M	—	—	Dec 31, 2022
2021	$3.23B	−$383.11M	—	—	Dec 31, 2021
2020	$3.41B	−$250.37M	—	—	Dec 31, 2020
2019	$2.13B	−$217.07M	—	—	Dec 31, 2019
2018	$1.01B	−$293.78M	—	—	Dec 31, 2018
2017	$2.39B	−$184.49M	—	—	Dec 31, 2017
2016	$815.67M	−$170.24M	—	—	Dec 31, 2016
2015	$1.11B	−$115.28M	—	—	Dec 31, 2015
2014	$754.39M	−$86.09M	—	—	Dec 31, 2014
2013	$666.21M	−$54.20M	—	—	Dec 31, 2013
2012	$210.28M	−$40.05M	—	—	Dec 31, 2012
2011	$75.79M	−$59.31M	—	—	Dec 31, 2011
2010	$118.68M	−$6.19M	—	—	Dec 31, 2010
2009	$100.26M	$120.31M	-0.2×	—	Dec 31, 2009
2008	$57.18M	−$13.81M	—	—	Dec 31, 2008
2007	$100.56M	−$20.03M	—	—	Dec 31, 2007
2006	$88.61M	−$51.00M	—	—	Dec 31, 2006
2005	$157.57M	−$14.54M	—	—	Dec 31, 2005
2004	$98.92M	−$27.39M	—	—	Dec 31, 2004
2003	$114.03M	−$10.49M	—	—	Dec 31, 2003
2002	$14.58M	−$34.15M	—	—	Dec 31, 2002
2001	$125.75M	−$38.64M	—	—	Dec 31, 2001


Gilead Sciences (GILD)	13.9×
Labcorp Holdings (LH)	13.6×
Amgen (AMGN)	13.6×
Charles River (CRL)	13.2×
Regeneron Pharmaceuticals (REGN)	12.9×
GE HealthCare (GEHC)	12.9×
UnitedHealth Group (UNH)	12.7×
Pfizer (PFE)	12.4×
Henry Schein (HSIC)	12.0×
Medtronic (MDT)	11.7×
AptarGroup (ATR)	11.5×
Bristol-Myers Squibb (BMY)	11.5×
Zimmer Biomet Holdings (ZBH)	11.2×
Biogen (BIIB)	10.5×
HCA Healthcare (HCA)	10.0×
Molina Healthcare (MOH)	8.8×
DaVita (DVA)	8.5×
IQVIA (IQV)	8.2×
Incyte (INCY)	7.9×
Cigna (CI)	7.8×
Elevance Health (ELV)	6.8×
Novo Nordisk (NVO)	6.5×
Solventum (SOLV)	5.8×
Universal Health Services (UHS)	5.7×
Humana (HUM)	4.5×

EV/EBITDA for Insmed (INSM)

EV/EBITDA daily chart for Insmed (INSM)

Historical EV/EBITDA for Insmed (INSM) from 2001 to 2025

About EV/EBITDA at Insmed (INSM)

Insmed EV/EBITDA by Year

Insmed EV/EBITDA 2009: -0.2×

Sector peers by EV/EBITDA — chart

Sector peers by EV/EBITDA — table

Frequently asked questions

Insmed (INSM) Key Financials

EV/EBITDA daily chart for Insmed (INSM)

Historical EV/EBITDA for Insmed (INSM) from 2001 to 2025

About EV/EBITDA at Insmed (INSM)

Insmed EV/EBITDA by Year

Insmed EV/EBITDA 2009: -0.2×

Sector peers by EV/EBITDA — chart

Sector peers by EV/EBITDA — table

Frequently asked questions

+What is Insmed's EV/EBITDA ratio?

+How is the EV/EBITDA ratio calculated?

+What is the EV/EBITDA ratio?

+What is a good EV/EBITDA ratio for Insmed?

+What is Insmed's historical EV/EBITDA ratio range?

+What was Insmed's EV/EBITDA ratio in 2009?

+Why does Insmed's EV/EBITDA ratio change over time?

+Why is Insmed's EV/EBITDA ratio not available?

Insmed (INSM) Key Financials